Breaking News

CMP Pharma, Kiel Labs In Drug Development Pact

By Kristin Brooks | March 3, 2014

To develop two NDA products in liquid dosage form

CMP Pharma and Kiel Laboratories have signed an agreement to develop and commercialize two new drug products. Both drugs are approved by the FDA in solid dosage forms and CMP will file NDAs to gain approval for an alternate liquid dosage form.
 
CMP Pharma is a specialty pharmaceutical company located in Farmville, NC that develops and manufactures a portfolio of high-value topical and liquid pharmaceutical products. Kiel Laboratories, Inc., located in Flowery Branch, GA, provides drug development, regulatory and intellectual property services, and specializes in identification of and regulatory strategies around 505(b)(2) NDA submissions.     
 
Gerald Sakowski, chief executive officer of CMP Pharma, said, “These two products are excellent complements to our line of niche specialty pharmaceutical products. This is another chapter in our long history of developing stable, ready-to-use liquid dosage forms that make life easier on the consumer, the physician and the pharmacist.”

Related Contract Manufacturing:

Related Packaging:

blog comments powered by Disqus
  • The Changing Biopharma Risk Landscape

    The Changing Biopharma Risk Landscape

    June 13, 2016
    Highlights biopharma industry's growth drivers and new approaches for mitigating risk

  • CROs and Today's R&D Landscape

    Kristin Brooks, Contract Pharma||May 11, 2016
    John Lewis of ACRO discusses opportunities and challenges, global markets, and the future CRO

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market